Quarterly Result3 Nov 2026, 06:11 pm
Jenburkt Pharmaceuticals Declares Standalone Unaudited Q2 FY27 Results
AI Summary
Jenburkt Pharmaceuticals Limited announced the outcome of its Board Meeting held on November 3, 2026. The Board approved and adopted the standalone unaudited financial statements for the quarter and half-year ended September 30, 2026. The Limited Audit Review Report from the company's auditors was also attached. The financial statements include the standalone Assets & Liabilities as of September 30, 2026, and the Cash Flow statement for the half-year ended on the same date.
Key Highlights
- Board approved standalone unaudited financial results for Q2 FY27.
- Results cover the quarter and half-year ended September 30, 2026.
- Audit Committee recommended the financial statements.
- Limited Audit Review Report from auditors is attached.
- Standalone Assets & Liabilities and Cash Flow statements are included.
Price Impact
More from JENBURPH